0102030405
Ivabradine CAS No. 155974-00-8 Pharmaceutical Raw Material
02
introduce
introduce
Ivabradine is a potent, oral selective If (funny current) channel blocker and key cardiovascular pharmaceutical API. It specifically slows heart rate without affecting myocardial contractility or blood pressure, approved for treating chronic heart failure and stable angina pectoris.
Our products adhere to strict international standards, ensuring high purity, stable performance, and reliable supply for clinical use and biomedical research.
02
Physical and chemical properties
Ivabradine exhibits critical physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Density: 1.1±0.1 g/cm3
- Flash Point: 332.9±31.5 °C
- Boiling Point: 626.9±55.0 °C at 760 mmHg
- Density: 1.1±0.1 g/cm3
- Flash Point: 332.9±31.5 °C
- Boiling Point: 626.9±55.0 °C at 760 mmHg
1. Unique and More Targeted Mechanism of Action
As the first selective and specific If inhibitor, it reduces heart rate by directly inhibiting the cardiac pacemaker If current. This mechanism is different from traditional anti-anginal drugs (such as beta-blockers and nitrates), which can accurately act on the pathways related to cardiac pacing and regulate cardiac function more targetedly.
2. Better Safety and Applicability to Special Populations
It can reduce heart rate in a dose-dependent manner without affecting blood pressure. Compared with beta-blockers and other drugs that may cause blood pressure fluctuations, it is more friendly to patients with stable blood pressure. Meanwhile, it is suitable for angina and heart failure patients who are intolerant to beta-blockers, filling the treatment gap for such patients.
As the first selective and specific If inhibitor, it reduces heart rate by directly inhibiting the cardiac pacemaker If current. This mechanism is different from traditional anti-anginal drugs (such as beta-blockers and nitrates), which can accurately act on the pathways related to cardiac pacing and regulate cardiac function more targetedly.
2. Better Safety and Applicability to Special Populations
It can reduce heart rate in a dose-dependent manner without affecting blood pressure. Compared with beta-blockers and other drugs that may cause blood pressure fluctuations, it is more friendly to patients with stable blood pressure. Meanwhile, it is suitable for angina and heart failure patients who are intolerant to beta-blockers, filling the treatment gap for such patients.
1. Core Indications: Used for the treatment of patients with chronic stable angina pectoris with normal sinus rhythm to relieve angina symptoms; its hydrochloride form can also be used for the treatment of heart failure patients (especially suitable for those intolerant to beta-blockers).
2. Other Related Effects: It has anticonvulsant and anti-ischaemic activities, which can assist in improving discomfort symptoms related to myocardial ischaemia and further help stabilize cardiac function.
2. Other Related Effects: It has anticonvulsant and anti-ischaemic activities, which can assist in improving discomfort symptoms related to myocardial ischaemia and further help stabilize cardiac function.
We implement strict full-process quality control, with each batch of Ivabradine undergoing rigorous testing of key indicators including purity, solubility, stability, protein binding rate, and biological activity to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and research needs.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and research needs.
As a first-in-class selective If channel inhibitor, Ivabradine has become an essential therapeutic option for chronic heart failure and angina, offering a unique mechanism of action distinct from traditional cardiovascular drugs. With its high selectivity, proven clinical efficacy, excellent safety profile, and reliable supply capacity, we are committed to providing high-quality Ivabradine API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Ivabradine to meet your needs in pharmaceutical formulation, cardiovascular research, and clinical treatment. Contact us for more product details and cooperation support.
Choose our Ivabradine to meet your needs in pharmaceutical formulation, cardiovascular research, and clinical treatment. Contact us for more product details and cooperation support.